| Index | — | P/E | — | EPS (ttm) | -3.01 | Insider Own | 6.33% | Shs Outstand | 78.53M | Perf Week | 2.91% |
| Market Cap | 2.36B | Forward P/E | — | EPS next Y | -4.23 | Insider Trans | 0.00% | Shs Float | 73.02M | Perf Month | -6.46% |
| Enterprise Value | 1.65B | PEG | — | EPS next Q | -1.02 | Short Float | 13.15% | Perf Quarter | -20.14% | ||
| Income | -259.00M | P/S | — | EPS this Y | — | Short Ratio | 7.06 | Perf Half Y | -6.84% | ||
| Sales | 2.00M | P/B | 3.31 | EPS next Y | — | ROA | -38.42% | Short Interest | 9.60M | Perf YTD | 10.82% |
| Book/sh | 9.10 | P/C | 3.29 | EPS next 5Y | — | ROE | -52.36% | 52W High | 45.14 -35.47% | Perf Year | 15.81% |
| Cash/sh | 9.14 | P/FCF | — | EPS past 3/5Y | — | ROIC | -45.10% | 52W Low | 22.10 31.81% | Perf 3Y | 28.09% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 0.00% -22.16% | Gross Margin | -56850.89% | Volatility | 3.41% 4.40% | Perf 5Y | -36.48% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | -290948.21% | ATR (14) | 1.39 | Perf 10Y | -41.67% |
| Dividend Ex-Date | — | Quick Ratio | 11.82 | Sales Y/Y TTM | -100.00% | Profit Margin | -268385.71% | RSI (14) | 45.45 | Recom | 2.20 |
| Dividend Gr. 3/5Y | — | Current Ratio | 11.82 | EPS Q/Q | -10.59% | SMA20 | 1.68% | Beta | 1.00 | Target Price | 66.80 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | -100.00% | SMA50 | -11.61% | Rel Volume | 0.65 | Prev Close | 30.10 |
| Employees | 198 | LT Debt/Eq | 0.00 | Earnings | Nov 09 | SMA200 | -7.81% | Avg Volume | 1.34M | Price | 29.13 |
| IPO Date | May 15, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 11.03% -97.01% | Net Debt/EBITDA | — | Volume | 870,775 | Change | -3.22% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-23-26 | Reiterated | Morgan Stanley | Overweight | $50 → $57 |
| Sep-23-26 | Reiterated | Leerink Partners | Outperform | $70 → $88 |
| Sep-22-26 | Reiterated | Stifel Nicolaus | $58 → $68 | |
| Sep-22-26 | Reiterated | HC Wainwright & Co. | Buy | $80 → $64 |
| Sep-10-26 | Reiterated | Morgan Stanley | Overweight | $40 → $50 |
| Aug-07-26 | Reiterated | Barclays | Overweight | $48 → $53 |
| Jul-29-26 | Reiterated | Wells Fargo | Overweight | $48 → $72 |
| Jul-22-26 | Reiterated | Leerink Partners | $78 → $70 | |
| Jul-22-26 | Reiterated | Cantor Fitzgerald | Overweight | $61 |
| Jul-22-26 | Reiterated | Morgan Stanley | Overweight | $46 → $40 |
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2 | 7 | 7 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 164 | 118 | — | — | — | — | — | — | |
| Gross Profit | 2 | -157 | -111 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 44 | 39 | 31 | — | — | — | — | — | — | |
| Research and Development | 245 | 164 | 118 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -164 | -106 | — | — | — | — | — | — | |
| Operating Income | -287 | -195 | -155 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 29 | 37 | 13 | — | — | — | — | — | — | |
| Net Income Before Taxes | -259 | -158 | -141 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -259 | -158 | -141 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -259 | -158 | -141 | — | — | — | — | — | — | |
| Net Income | -259 | -158 | -141 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.90 | -2.45 | -2.92 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.90 | -2.45 | -2.92 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.90 | -2.45 | -2.92 | — | — | — | — | — | — | |
| EBITDA | -255 | -155 | -139 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 909.86 | 231.04 | 271.95 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | -2,242.86 | -1,585.71 | — | — | — | — | — | — | |
| Operating Margin | -14,350.00 | -2,785.71 | -2,214.29 | — | — | — | — | — | — | |
| Net Margin | -12,950.00 | -2,257.14 | -2,014.29 | — | — | — | — | — | — | |
| Shares Outstanding | 67 | 64 | 48 | — | — | — | — | — | — | |
| Market Capitalization | 1,820 | 1,617 | 1,904 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Martin Samuel Bates | SVP AND CFO | Jan 02 '26 | Option Exercise | 10.38 | 4,817 | 50,000 | 32,942 | Jan 06 |
| PEPIN RONALD | SR. VP & CBO | Dec 15 '25 | Option Exercise | 5.47 | 19,333 | 105,714 | 20,097 | Dec 17 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | Dec 04 '25 | Sale | 29.09 | 4,166 | 121,210 | 30,796 | Dec 08 |
| Wright Richard M. | Former Officer | Nov 13 '25 | Option Exercise | 14.06 | 49,298 | 692,912 | 70,131 | Nov 17 |
| Wright Richard M. | Former Officer | Nov 13 '25 | Sale | 24.00 | 49,298 | 1,183,177 | 20,833 | Nov 17 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL | Aug 13 '25 | Sale | 24.77 | 771 | 19,095 | 34,962 | Aug 15 |
| Marucci Anthony S | PRESIDENT & CEO | Nov 11 '24 | Buy | 26.82 | 11,500 | 308,430 | 40,284 | Nov 12 |
| Martin Samuel Bates | SVP AND CFO | Jun 14 '24 | Option Exercise | 10.16 | 20,169 | 204,990 | 45,297 | Jun 18 |
| Martin Samuel Bates | SVP AND CFO | Jun 14 '24 | Sale | 35.42 | 17,172 | 608,315 | 28,125 | Jun 18 |
| Crowley Elizabeth | SR. VP & CPDO | Jun 14 '24 | Option Exercise | 10.38 | 30,000 | 311,400 | 39,074 | Jun 18 |
| Crowley Elizabeth | SR. VP & CPDO | Jun 14 '24 | Sale | 34.87 | 30,000 | 1,045,962 | 9,074 | Jun 18 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Jun 11 '24 | Option Exercise | 2.71 | 15,000 | 40,650 | 17,115 | Jun 13 |
| Crowley Elizabeth | SR. VP & CPDO | Jun 07 '24 | Option Exercise | 9.70 | 15,000 | 145,474 | 24,074 | Jun 11 |
| Crowley Elizabeth | SR. VP & CPDO | Jun 07 '24 | Sale | 35.06 | 15,000 | 525,873 | 9,074 | Jun 11 |
| Young Diane C. | SVP, CHIEF MEDICAL OFFICER | Jun 07 '24 | Sale | 35.26 | 45,000 | 1,586,844 | 2,115 | Jun 11 |